CALDEIRÃO DE BOLSA

E já agora fica o gráfico. No mínimo é de ficar impressionado!!

U R G E N T I N V E S T O R A L E R T

Discover how a $5,000 biotech investment could easily swell to $10,000 or
more in 18 months!

Let me tell you about a biotech firm with several breakthrough
discoveries. One is a SARS vaccine.

After new cases of SARS were confirmed earlier this year, it appears that
this infectious disease is threatening the global population once again.

But this time, scientists at Sinovac have a head start. After nine months
of research and development, they recently received approval to conduct
the very first human clinical trials for the SARS vaccine. Their next
goal is to roll out the first-ever vaccine for the disease, a move that
could deliver double or triple profits to early investors.

If you're ready to profit, here's what you need to know... If you would
like a German translation of this email click here.

Richard Schmidt
Homerun Stock Alert

Dear Investor,

An exciting new biotech stock recently showed up on my radar, and since
it promises to become one of my biggest winners yet, I wanted to tell you
about it immediately.

As a publicly traded U.S. company, Sinovac Biotech Ltd. has the potential
to successfully tap the worldwide vaccine market for several of the
world's most widespread diseases. And while the risk level is high, so is
the upside potential.

COMPANY OVERVIEW

With every new infectious disease that shows up on the world scene,
whether it's SARS or an exotic strain of influenza, the demand for human
vaccines grows by leaps and bounds. For this reason, Sinovac is becoming
more and more attractive to investors who are looking for an aggressive
stock that can provide them with hefty returns.

Based in Beijing, China, Sinovac has quietly carved out a name for itself
by focusing on the research, development and commercialization of human
vaccines. As a result, the company is already at the forefront of the
Chinese vaccine market and is expanding internationally as well.

In the global race to create a safe and effective vaccine for SARS,
Sinovac is at least a year ahead of the competition. What's more, the
market potential of the vaccine is enormous since the disease can infect
people of all ages, anywhere in the world.

The company has already successfully launched Healive™, its hepatitis A
vaccine, in 2002. In fact, the vaccine sold an estimated 450,000 units
for about USD $7 per unit in its first full year of production. According
to the Sinovac management team, strong sales should continue through at
least the next five years.

Sinovac also has several other proprietary vaccines in the pipeline,
including an influenza vaccine as well as a combination hepatitis A & B
vaccine.

RECOMMENDATION

Since this is my #1 biotech stock recommendation for aggressive investors
in 2004, I strongly urge you to learn more about Sinovac by visiting
http://direct.lycos.com/redir/04030201_ ... roughstock. While there, you can also find out how
to regularly receive other Homerun Stock Alert recommendations like this.

Mark my words: Keep following my recommendations on this rising star and
in 18 months or less, your $5,000 investment could easily turn into
$10,000!

To invest in Sinovac Biotech, Ltd. (OTCBB: SNVBF) now, go online or
contact your discount broker.

Richard Schmidt
Homerun Stock Alert

Name of stock: Sinovac Biotech Co., Ltd.
Symbol: OTCBB: SNVBF
Low projection: $5.50
High projection: $8.25
RECOMMENDATION: STRONG BUY


WHO IS RICHARD SCHMIDT?
He's a two-time winner of The Wall Street Journal's stock picking
contest, and a regular contributor to CNN's Moneyline, the Nightly
Business Report, Money Talk and dozens of other media channels and
publications. Considered to be America's #1 turnaround expert, he's built
an extraordinary record as an investment advisor, beating the Dow every
year for 12 years in a row. The stock featured in this email alert can be
found in his current edition of the Homerun Stock Alert newsletter.


Disclaimer: Homerun Stock Alert is an independent newsletter. Homerun Stock
Alert's goal is to give the investor the necessary knowledge to make
rational and profitable investment decisions. Homerun Stock Alert received
no monetary compensation with respect to the writing of this special
report. Homerun Stock Alert expects to generate new subscriber revenue, the
amount of which is unknown at this time, to its newsletter through the
distribution of this special report. Compensation associated with
distribution to possible new subscribers in the amount of $73,075 was paid
for by Technique Capital as an effort to build investor awareness for
Sinovac Biotech, Ltd. This publication does not provide an analysis of a
company's financial position and is not an offer to buy or sell securities.
Sinovac Biotech's financial position and all information should be verified
with the company. Information about publicly listed companies and other
investor resources can be found at the Securities & Exchange Commission
website www.sec.gov. Investing in securities is speculative and carries
risk. It is recommended any investment in any security should be made only
after consulting with your investment advisor and only after reviewing the
prospectus or financial statements of the company. Homerun Stock Alert
presents information in this report believed to be reliable, but its
accuracy cannot be guaranteed. Past performance does not guarantee future
results. The information contained herein contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1993 and Section 21E of the Securities Exchange Act of
1934, including statements regarding expected continual growth of the
featured company. In accordance with safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, that statements contained herein
that look forward in time, which include other than historical information,
involve risks and uncertainties that may affect actual results of
operations. Factors that could cause actual results to differ include the
size and growth of the market for the company's products, the company's
ability to fund its capital requirements in the near term and in the long
term; pricing pressures, etc. Any statements that express or involve
discussions with respect to predictions, expectations, beliefs, plans,
projections, objectives, goals, assumptions or future events or performance
may be forward-looking statements. Forward-looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward-looking statements may be identified through the use of words such
as expects, will, anticipates, estimates, believes, or by statements
indicating certain actions may, could, should or might occur.

Homerun Stock Alert
5633 Strand Blvd. Suite 318 • PO Box 110597
Naples, FL 34108-9849
Call to order: 1-800-663-2185 24 hours a day, 7 days a week
Fax: 1-239-591-3181
http://direct.lycos.com/redir/04030201_ ... roughstock


***********************************************************************
Thank you for subscribing to Lycos Special Offers.

You opted to receive Lycos Special Offers when you registered
with the Lycos Network. Subscription preferences can be changed at:
http://ldbreg.lycos.com/cgi-bin/mayaReg ... P=1&m_RC=3

Please do not reply directly to this email. However if you would like
to stop receiving Lycos Special Offers at grandeguloso@sapo.pt,
please click on the following link.
http://ldbreg.lycos.com/cgi-bin/mayaEma ... ddmcPkhQAA

If you would like to review our privacy policy it can be accessed at:
http://info.lycos.com/privacy/privacy.asp

Lycos, Inc. is not responsible for the advertisers'
content, products or services.

Lycos, Inc., 100 Fifth Avenue, MS 248, Waltham, MA, 02451